



July 25, 2025
JCR Pharmaceuticals Co., Ltd.

Notice Regarding the Completion of Payment for the Disposition of Treasury Stock as Restricted Stock Compensation

Hyogo, Japan – July 25, 2025 – [JCR Pharmaceuticals Co., Ltd.](#) (TSE 4552; “JCR”) announces the completion today of payment procedures for the disposition of treasury stock as restricted stock compensation, in accordance with the resolution at the meeting of the Board of Directors on June 25, 2025. For more details, please refer to the “[Notice Regarding the Disposition of Treasury Stock as Restricted Stock Compensation](#)” on June 25, 2025.

Overview of the Disposition of Treasury Stock

(1)	Type and Number of Shares to be Disposed of	111,000 shares of JCR’s common stock
(2)	Disposition Price	518 yen per share
(3)	Total Disposition Amount	57,498,000 yen
(4)	Recipients of Disposition, Number of Recipients and the Number of Shares to be Disposed of	<p>Directors of JCR 10 individuals, 71,000 shares</p> <p>Executive officers who do not concurrently serve as directors of JCR 6 individuals, 33,000 shares</p> <p>Employees of JCR 1 individuals, 2,000 shares</p> <p>Directors of JCR’s subsidiaries (concurrent) 1 individuals, 5,000 shares</p>
(5)	Disposition Date	July 25, 2025

About JCR Pharmaceuticals Co., Ltd.

JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceutical company that develops treatments that go beyond rare diseases to solve the world’s most complex healthcare challenges. We continue to build upon our 50-year legacy in Japan while expanding our global footprint into the U.S., Europe, and Latin America. We improve patients’ lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, MPS II (Hunter syndrome), Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II, MPS IIIA and B (Sanfilippo syndrome type A and B), and more. Our core values – Putting people first, Forging our own path, Always advancing, and Committed to excellence – mean that the work we do benefits all our stakeholders, including partners, patients and employees. We strive to expand the possibilities

for patients while accelerating medical advancement at a global level. For more information, please visit JCR's global website: <https://jcrpharm.com/>.

Contact:

Investors & Media:

JCR Pharmaceuticals Co., Ltd.

Corporate Communications

ir-info@jp.jcrpharm.com

###